After several decades of hard work by many scientists at the University of Michigan Medical School and elsewhere, an antibody (anti-C5a) has just been approved by the US FDA for treatment of humans who are septic and have developed lung infections with COVID-19, resulting in severe pulmonary dysfunction requiring external lung support. The antibody, anti-C5a, was originally developed in the Dr. Peter Ward laboratory in the early 2000s. The mAb was shown to dramatically reduce lung infections in polymicrobial sepsis in mice.
A Perspective with Jessica McAnulty, MCP Student
Dr. Mehra discusses his career path and how he arrived at Michigan Medicine in our latest Careers in Pathology video.
A new publication, generated by Department of Pathology faculty members Drs. Aaron Udager and Scott Tomlins was successfully published in European Urology. The research highlights a longitudinal cohort study centered around the serial molecular profiling of low-grade prostate cancer in order to better assess tumor upgrading [...]
Clinical trials underway are testing whether drugs that target the androgen receptor – successful in controlling prostate cancer – could also work against the coronavirus. wo proteins, ACE2 and TMPRSS2, help the coronavirus gain entry and replicate within cells. TMPRSS2 is well-known to Arul Chinnaiyan, MD, PhD. His lab discovered that TMPRSS2 fuses with the ETS gene to drive more than half of all prostate cancers [...]
11:30 am EST
Join us for a virtual event featuring the Department of Pathology's Dr. Arul Chinnaiyan, who will give the 2020 American Society for Investigative Pathology (ASIP)'s Rous-Whipple Award Lecture.
The research, which focuses on invasive squamous cell carcinomas and the precursor lesions that demonstrate concordic genomic complexity in driver genes, was just published in Modern Pathology.